Emil Soorani
Santa Monica, CANPI 1053434472
Payments from drug & device makers
Across 377 payments — averaging $68.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Vanda Pharmaceuticals Inc.$945
- Otsuka America Pharmaceutical, Inc.$914
- Bausch Health US, LLC$567
- Takeda Pharmaceuticals U.S.A., Inc.$555
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$532
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$15,05059%
- Travel & lodging$4152%
- Food & beverage$10,08939%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 146 | $19,313 |
| Vanda Pharmaceuticals Inc. | 31 | $945 |
| Otsuka America Pharmaceutical, Inc. | 28 | $914 |
| Bausch Health US, LLC | 36 | $567 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $555 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $532 |
| Axsome Therapeutics, Inc. | 19 | $524 |
| Lundbeck LLC | 12 | $317 |
| Alkermes, Inc. | 9 | $286 |
| Harmony Biosciences LLC | 8 | $274 |
| Idorsia Pharmaceuticals US Inc | 3 | $219 |
| Teva Pharmaceuticals USA, Inc. | 4 | $206 |
| Johnson & Johnson | 7 | $171 |
| Jazz Pharmaceuticals Inc. | 2 | $139 |
| Sunovion Pharmaceuticals Inc. | 1 | $124 |
| Neurocrine Biosciences, Inc. | 4 | $112 |
| Shire North American Group Inc | 5 | $99 |
| Adlon Therapeutics L.p. | 5 | $98 |
| Neos Therapeutics, LP | 4 | $94 |
| Arbor Pharmaceuticals, Inc. | 3 | $66 |
| Avanir Pharmaceuticals, Inc. | 2 | $49 |
| Merck | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Sentynl Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 56 | $87,693 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $19,546 |
| VraylarCariprazine Hcl | 13 | $17,432 |
| Memantine Hcl ErMemantine Hcl | 102 | $10,491 |
| FetzimaLevomilnacipran Hcl | 17 | $8,578 |
| Lisdexamfetamine Dimesylate | 36 | $8,278 |
| BelsomraSuvorexant | 17 | $7,902 |
| ZenzediDextroamphetamine Sulfate | 11 | $6,103 |
| DayvigoLemborexant | 17 | $5,677 |
| Armodafinil | 99 | $5,042 |
| Amphetamine Sulfate | 11 | $3,756 |
| Bupropion XlBupropion Hcl | 187 | $3,510 |
| Aripiprazole | 84 | $2,818 |
| Quetiapine Fumarate | 86 | $2,757 |
| Vilazodone Hcl | 34 | $2,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $914 | $87,69356 claims |
| AbbVieVraylar, Fetzima, Synthroid | $19,313 | $26,49741 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $555 | $19,54638 claims |
| MerckBelsomra | $30 | $7,90217 claims |
| Arbor Pharmaceuticals, Inc.Zenzedi | $66 | $6,10311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.